Coave Therapeutics to Present Novel Data Highlighting the Potential of its ALIGATER™ Platform to Enhance the Targeted Delivery of Genetic Medicines at Upcoming Conferences

Paris, France, September 24, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company pioneering therapies for eye and neurodegenerative diseases, will present the first data on its peptide-conjugated vector technology, a key new component of its ALIGATER™ (Advanced Vectors-Ligand Conjugates) platform technology at upcoming conferences. This breakthrough technology not only enables the redirection of AAV (adeno-associated virus) and LNP (lipid nanoparticle) vectors to specific receptors of interest but also the modulation of vector/receptor affinity, offering enhanced gene delivery option for precision medicines.

CEO Rodolphe Clerval will present the Company’s progress at the following investor conferences:

• Chardan’s 8th Annual Genetic Medicines Conference – September 30 – October 1
  • New York City, NY, USA
  • Presenting on September 30 at 13.30 EDT

• Jefferies London Healthcare Conference – November 19-21
  • London, UK
  • Available for investor meetings

• In addition, Coave will present new scientific data from its ALIGATER™ platform at the following scientific, medical and regulatory conference: European Society of Gene and Cell Therapy (ESGCT) 31^st Annual Congress – October 22-25
  • Rome, Italy
  • Poster title: “The Advanced Ligand Conjugation (ALIGATER™) platform chemically redirects AAV and LNP vectors towards specific receptors via peptide-mediated targeting.”
  • Presenting on 23 October, 13.30-15.00 CEST (Poster ID# P0074)

***

About Coave Therapeutics

At Coave Therapeutics, we are leading the transition of genetic medicine from rare to prevalent conditions, starting with neurodegenerative and eye diseases. Our proprietary ALIGATER™ (Advanced Vectors-Ligand Conjugates) platform introduces chemical modifications onto AAV capsids or Lipid Nanoparticles (LNPs) to overcome the limitations of current vectors on efficacy, safety, and manufacturability. 

With low doses and optimized routes of administration, our conjugated vectors have demonstrated markedly improved transduction and biodistribution in the central nervous system and the eye across different species. Our diverse pipeline of novel genetic medicines can potentially transform the lives of people afflicted by rare and prevalent neurodegenerative and ocular diseases – including genetically and non-genetically defined indications. 

Headquartered in Paris, France, Coave Therapeutics is backed by leading international life sciences investors. For more information about the science, pipeline, and people, please visit https://coavetx.com/ and follow us on LinkedIn. 

CONTACTS 
Coave Therapeutics 
Rodolphe Clerval, CEO 
contact@coavetx.com   

MEDiSTRAVA
Sylvie Berrebi, Leila Adlam, Mark Swallow 
coavetx@medistrava.com